Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Multiple Sclerosis

Free Subscription Articles published in Ann Neurol Retrieve available abstracts of 55 articles: HTML format

Single Articles

October 2025
1. SIMPSON-YAP S, Morwitch E, Tanner SA, Thomson SM, et al
   Epstein-Barr Virus, Lower Vitamin D, Low Sun Exposure, and HLA-DRB1*1501 Risk Variant Share Common Epigenetic Pathways Leading to Multiple Sclerosis Onset.
   Ann Neurol. 2025 Oct 10. doi: 10.1002/ana.78043.
   PubMed     Abstract available
   
   
   
2. GHEZZI L, Kosa P, Greenwood M, Alvarez E, et al
   From Diagnosis to Disease Staging: Multisite Validation of Cerebrospinal Fluid Molecular Tests in Multiple Sclerosis.
   Ann Neurol. 2025 Oct 3. doi: 10.1002/ana.78047.
   PubMed     Abstract available
   
   
   September 2025
3. BREVILLE G, Benkhoucha M, Rezk A, Tran NL, et al
   Pro-Inflammatory c-Met(+) CD4 T Cells in Multiple Sclerosis.
   Ann Neurol. 2025 Sep 26. doi: 10.1002/ana.78035.
   PubMed     Abstract available
   
   
   
4. SIAVOSHI F, Smith MD, Cassard S, Moreau GB, et al
   Fasting Mimicking Diets Reverse Accelerated Biological Aging in Multiple Sclerosis.
   Ann Neurol. 2025 Sep 19. doi: 10.1002/ana.78044.
   PubMed     Abstract available
   
   
   
5. CERONO G, Cree BAC, Hauser SL, Baranzini SE, et al
   Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.
   Ann Neurol. 2025 Sep 8. doi: 10.1002/ana.78033.
   PubMed     Abstract available
   
   
   August 2025
6. MANOUCHEHRINIA A, Fitzgerald KC, Salter A, Marrie RA, et al
   Depression Polygenicity and Disease Activity and Disability Worsening in Multiple Sclerosis.
   Ann Neurol. 2025 Aug 7. doi: 10.1002/ana.70020.
   PubMed     Abstract available
   
   
   July 2025
7. CREE BAC, Freedman MS, Gold M, Pfleeger K, et al
   Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose Studies to Assess the Safety and Efficacy of Elezanumab when Added to Standard of Care in Relapsing and Progressive Forms of Multiple Sclerosis.
   Ann Neurol. 2025 Jul 23. doi: 10.1002/ana.27262.
   PubMed     Abstract available
   
   
   June 2025
8. SACCO S, Papinutto N, Schoeps VA, Cheng S, et al
   High-Dose Pulse Glucocorticoid Treatment Prevents White Matter Spinal Cord Pseudoatrophy in Newly Diagnosed Multiple Sclerosis.
   Ann Neurol. 2025 Jun 24. doi: 10.1002/ana.27298.
   PubMed     Abstract available
   
   
   
9. DISANTO G, Sacco R, Mallucci G, Zecca C, et al
   Effect of Cumulative Exposure to Ocrelizumab on Memory B-Cell Repopulation Dynamics in Multiple Sclerosis.
   Ann Neurol. 2025 Jun 11. doi: 10.1002/ana.27281.
   PubMed     Abstract available
   
   
   
10. SABATINO JJ JR, Cree BAC, Hauser SL
    New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond.
    Ann Neurol. 2025 Jun 6. doi: 10.1002/ana.27270.
    PubMed     Abstract available
    
    
    April 2025
11. POOLE S, Sisodia N, Koshal K, Henderson K, et al
    Detecting New Lesions Using a Large Language Model: Applications in Real-World Multiple Sclerosis Datasets.
    Ann Neurol. 2025 Apr 25. doi: 10.1002/ana.27251.
    PubMed     Abstract available
    
    
    
12. MURARO PA, Zito A, Signori A, Sormani MP, et al
    Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study.
    Ann Neurol. 2025 Apr 19. doi: 10.1002/ana.27247.
    PubMed     Abstract available
    
    
    
13. PANSIERI J, Pisa M, Yee S, Gutnikova A, et al
    Neuropathological Evidence of Reduced Amyloid Beta and Neurofibrillary Tangles in Multiple Sclerosis Cortex.
    Ann Neurol. 2025 Apr 8. doi: 10.1002/ana.27231.
    PubMed     Abstract available
    
    
    February 2025
14. ABBADESSA G, Nagano A, Hametner S, Howell O, et al
    Mapping Molecular Pathways of Multiple Sclerosis: A Gene Prioritization and Network Analysis of White Matter Pathology Transcriptomics.
    Ann Neurol. 2025 Feb 14. doi: 10.1002/ana.27216.
    PubMed     Abstract available
    
    
    
15. PAPADOPOULOS D, Magliozzi R, Bandiera S, Cimignolo I, et al
    Accelerated Cellular Senescence in Progressive Multiple Sclerosis: A Histopathological Study.
    Ann Neurol. 2025 Feb 1. doi: 10.1002/ana.27195.
    PubMed     Abstract available
    
    
    January 2025
16. MARGONI M, Storelli L, Pagani E, Preziosa P, et al
    Subventricular Zone Microstructure in Pediatric-Onset Multiple Sclerosis.
    Ann Neurol. 2025 Jan 18. doi: 10.1002/ana.27180.
    PubMed     Abstract available
    
    
    December 2024
17. BRIER MR, Judge B, Ying C, Salter A, et al
    Increased White Matter Aerobic Glycolysis in Multiple Sclerosis.
    Ann Neurol. 2024 Dec 23. doi: 10.1002/ana.27165.
    PubMed     Abstract available
    
    
    November 2024
18. BROWNLEE WJ, Vidal-Jordana A, Shatila M, Strijbis E, et al
    Towards a Unified Set of Diagnostic Criteria for Multiple Sclerosis.
    Ann Neurol. 2024 Nov 28. doi: 10.1002/ana.27145.
    PubMed     Abstract available
    
    
    
19. PROTOPAPA M, Steffen F, Schraad M, Ruck T, et al
    Increased Disability Progression in rs10191329(AA) Carriers with Multiple Sclerosis Is Preceded by Neurofilament Light Chain Elevations.
    Ann Neurol. 2024 Nov 26. doi: 10.1002/ana.27144.
    PubMed     Abstract available
    
    
    
20. MEUTH SG, Wolff S, Muck A, Willison A, et al
    Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
    Ann Neurol. 2024 Nov 25. doi: 10.1002/ana.27143.
    PubMed     Abstract available
    
    
    October 2024
21. ALZAMANAN F, Ding Y, Harroud A
    Obesity and Multiple Sclerosis Severity: A Mendelian Randomization Study.
    Ann Neurol. 2024 Oct 21. doi: 10.1002/ana.27112.
    PubMed     Abstract available
    
    
    
22. MESSMER ML, Salapa HE, Popescu BF, Levin MC, et al
    RNA Binding Protein Dysfunction Links Smoldering/Slowly Expanding Lesions to Neurodegeneration in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 18. doi: 10.1002/ana.27114.
    PubMed     Abstract available
    
    
    
23. BENKERT P, Maleska Maceski A, Schaedelin S, Oechtering J, et al
    Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 16. doi: 10.1002/ana.27096.
    PubMed     Abstract available
    
    
    
24. SANABRIA-DIAZ G, Cagol A, Lu PJ, Barakovic M, et al
    Advanced MRI Measures of Myelin and Axon Volume Identify Repair in Multiple Sclerosis.
    Ann Neurol. 2024 Oct 10. doi: 10.1002/ana.27102.
    PubMed     Abstract available
    
    
    
25. MONTOBBIO N, Cordioli C, Signori A, Bovis F, et al
    Relapse-Associated and Relapse-Independent Contribution to Overall Expanded Disability Status Scale Progression in Multiple Sclerosis Patients Diagnosed in Different Eras.
    Ann Neurol. 2024 Oct 9. doi: 10.1002/ana.27093.
    PubMed     Abstract available
    
    
    September 2024
26. FADDA G, Banwell B, Elliott C, Fetco D, et al
    Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease.
    Ann Neurol. 2024 Sep 7. doi: 10.1002/ana.27066.
    PubMed     Abstract available
    
    
    August 2024
27. GRUT V, Bistrom M, Salzer J, Stridh P, et al
    Interactions between High Seroreactivity to Human Herpes Virus 6A and Epstein-Barr Virus in MS Development: A Presymptomatic Case-Control Study.
    Ann Neurol. 2024;96:302-305.
    PubMed     Abstract available
    
    
    July 2024
28. MARRODAN M, Calandri IL, Bocancea DI, Ysrraelit MC, et al
    Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis.
    Ann Neurol. 2024 Jul 26. doi: 10.1002/ana.27043.
    PubMed     Abstract available
    
    
    
29. SCALFARI A, Traboulsee A, Oh J, Airas L, et al
    Smouldering-Associated Worsening in Multiple Sclerosis: An International Consensus Statement on Definition, Biology, Clinical Implications, and Future Directions.
    Ann Neurol. 2024 Jul 25. doi: 10.1002/ana.27034.
    PubMed     Abstract available
    
    
    
30. HU Y, Frisell T, Alping P, Song H, et al
    Hospital-Treated Infections and Risk of Disability Worsening in Multiple Sclerosis.
    Ann Neurol. 2024 Jul 10. doi: 10.1002/ana.27026.
    PubMed     Abstract available
    
    
    
31. BRIER MR, Schindler SE, Salter A, Perantie D, et al
    Unexpected Low Rate of Amyloid-beta Pathology in Multiple Sclerosis Patients.
    Ann Neurol. 2024 Jul 4. doi: 10.1002/ana.27027.
    PubMed     Abstract available
    
    
    June 2024
32. PIEHL F, Alping P, Virtanen S, Englund S, et al
    COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.
    Ann Neurol. 2024 Jun 25. doi: 10.1002/ana.27012.
    PubMed     Abstract available
    
    
    May 2024
33. CORTESE R, Battaglini M, Prados F, Gentile G, et al
    Grey Matter Atrophy and its Relationship with White Matter Lesions in Patients with Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Multiple Sclerosis.
    Ann Neurol. 2024 May 23. doi: 10.1002/ana.26951.
    PubMed     Abstract available
    
    
    
34. GIORDANO A, Pignolet B, Mascia E, Clarelli F, et al
    DNA Methylation in the Anti-Mullerian Hormone Gene and the Risk of Disease Activity in Multiple Sclerosis.
    Ann Neurol. 2024 May 15. doi: 10.1002/ana.26959.
    PubMed     Abstract available
    
    
    April 2024
35. CALABRESE M, Preziosa P, Scalfari A, Colato E, et al
    Determinants and Biomarkers of Progression Independent of Relapses in Multiple Sclerosis.
    Ann Neurol. 2024 Apr 3. doi: 10.1002/ana.26913.
    PubMed     Abstract available
    
    
    March 2024
36. NEIDHART S, Vlad B, Hilty M, Hogelin KA, et al
    HLA Associations of Intrathecal IgG Production against Specific Viruses in Multiple Sclerosis.
    Ann Neurol. 2024 Mar 29. doi: 10.1002/ana.26921.
    PubMed     Abstract available
    
    
    
37. ALPING P, Neovius M, Piehl F, Frisell T, et al
    Real-World Healthcare Cost Savings and Reduced Relapse Rate with Off-Label Rituximab versus Disease-Modifying Treatments Approved for Relapsing-Remitting Multiple Sclerosis: A Nationwide Cost-Effectiveness Study.
    Ann Neurol. 2024 Mar 26. doi: 10.1002/ana.26914.
    PubMed     Abstract available
    
    
    
38. MARGONI M, Pagani E, Meani A, Preziosa P, et al
    Cognitive Impairment Is Related to Glymphatic System Dysfunction in Pediatric Multiple Sclerosis.
    Ann Neurol. 2024 Mar 13. doi: 10.1002/ana.26911.
    PubMed     Abstract available
    
    
    February 2024
39. FADDA G, Yea C, O'Mahony J, Waters P, et al
    Epstein-Barr Virus Strongly Associates With Pediatric Multiple Sclerosis, But Not Myelin Oligodendrocyte Glycoprotein-Antibody-Associated Disease.
    Ann Neurol. 2024 Feb 27. doi: 10.1002/ana.26890.
    PubMed     Abstract available
    
    
    
40. CHOMYK A, Kucinski R, Kim J, Christie E, et al
    Transcript Profiles of Microglia/Macrophage Cells at the Borders of Chronic Active and Subpial Gray Matter Lesions in Multiple Sclerosis.
    Ann Neurol. 2024 Feb 12. doi: 10.1002/ana.26877.
    PubMed     Abstract available
    
    
    December 2023
41. NICHOLAS R, Magliozzi R, Marastoni D, Howell O, et al
    High levels of perivascular inflammation and active demyelinating lesions at time of death associated with rapidly progressive multiple sclerosis disease course: a retrospective post-mortem cohort study.
    Ann Neurol. 2023 Dec 27. doi: 10.1002/ana.26870.
    PubMed     Abstract available
    
    
    
42. MCKAY KA, Wijnands JMA, Manouchehrinia A, Zhu F, et al
    Risk of Multiple Sclerosis in People Living with HIV: An International Cohort Study.
    Ann Neurol. 2023 Dec 14. doi: 10.1002/ana.26840.
    PubMed     Abstract available
    
    
    
43. KIM S, Eun MY, Lee JJ, Seok HY, et al
    Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions.
    Ann Neurol. 2023 Dec 12. doi: 10.1002/ana.26859.
    PubMed    
    
    
    
44. VILLACIEROS-ALVAREZ J, Espejo C, Cobo-Calvo A
    Reply to "Myelin Oligodendrocyte Glycoprotein Antibody-Positive Patients Meeting the 2017 McDonald Criteria for Multiple Sclerosis: Challenges in Diagnosis and Treatment Decisions".
    Ann Neurol. 2023 Dec 11. doi: 10.1002/ana.26856.
    PubMed    
    
    
    
45. KNOWLES S, Middleton R, Cooze B, Farkas I, et al
    Comparing the pathology, clinical and demographic characteristics of younger and older-onset multiple sclerosis.
    Ann Neurol. 2023 Dec 7. doi: 10.1002/ana.26843.
    PubMed     Abstract available
    
    
    November 2023
46. KREFT KL, Uzochukwu E, Loveless S, Willis M, et al
    Relevance of multiple sclerosis severity genotype in predicting disease course: A real-world cohort.
    Ann Neurol. 2023 Nov 17. doi: 10.1002/ana.26831.
    PubMed     Abstract available
    
    
    September 2023
47. GASPERI C, Wiltgen T, McGinnis J, Cerri S, et al
    A genetic risk variant for multiple sclerosis severity is associated with brain atrophy.
    Ann Neurol. 2023 Sep 27. doi: 10.1002/ana.26807.
    PubMed     Abstract available
    
    
    
48. VILLACIEROS-ALVAREZ J, Espejo C, Arrambide G, Castillo M, et al
    MOG antibodies in adults with a first demyelinating event suggestive of multiple sclerosis.
    Ann Neurol. 2023 Sep 14. doi: 10.1002/ana.26793.
    PubMed     Abstract available
    
    
    August 2023
49. ADINGUPU DD, Evans T, Soroush A, Hansen A, et al
    Temporal pattern of cortical hypoxia in Multiple Sclerosis and its significance on neuropsychological and clinical measures of disability.
    Ann Neurol. 2023 Aug 22. doi: 10.1002/ana.26769.
    PubMed     Abstract available
    
    
    July 2023
50. SORMANI MP, Schiavetti I, Ponzano M, Colato E, et al
    Treatment Effect on Brain Atrophy Correlates with Treatment Effect on Cognition in Multiple Sclerosis.
    Ann Neurol. 2023 Jul 26. doi: 10.1002/ana.26751.
    PubMed     Abstract available
    
    
    June 2023
51. CLARK KA, Manning AR, Chen L, Liu F, et al
    Early MRI features of new paramagnetic rim lesions in Multiple Sclerosis.
    Ann Neurol. 2023 Jun 21. doi: 10.1002/ana.26727.
    PubMed     Abstract available
    
    
    May 2023
52. HOLM HANSEN R, von Essen MR, Mahler MR, Cobanovic S, et al
    Cladribine effects on T and B cells and T cell reactivity in multiple sclerosis.
    Ann Neurol. 2023 May 16. doi: 10.1002/ana.26684.
    PubMed     Abstract available
    
    
    
53. PATRICK MT, Nair RP, He K, Stuart PE, et al
    Shared Genetic Risk Factors for Multiple Sclerosis/Psoriasis Suggest Involvement of Interleukin-17 and Janus Kinase-Signal Transducers and Activators of Transcription Signaling.
    Ann Neurol. 2023 May 1. doi: 10.1002/ana.26672.
    PubMed     Abstract available
    
    
    April 2023
54. HAMZAOUI M, Garcia J, Boffa G, Lazzarotto A, et al
    Positron emission tomography with [(18) F]-DPA-714 unveils a smoldering component in most multiple sclerosis lesions which drives disease progression.
    Ann Neurol. 2023 Apr 11. doi: 10.1002/ana.26657.
    PubMed     Abstract available
    
    
    March 2023
55. BAKIRTZIS C, Langdon DW, Grigoriadis N
    Time to rebaseline cognitive performance in people with multiple sclerosis?
    Ann Neurol. 2023 Mar 8. doi: 10.1002/ana.26628.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge.